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Atrial fibrillation is a common cardiac arrhythmia 
associated with debilitating complications, one of which 
is stroke. Anticoagulants (warfarin and the non-vitamin 
K antagonist oral anticoagulants) are recommended for 
stroke prophylaxis, their utilisation however requires 
stroke risk reduction to be balanced against hemorrhage 
risk. Current review of the literature suggests that 
despite the presence of risk stratification tools such as 
the CHADS2 and the newer CHA2DS2-VASc, clinicians 
often find it challenging to anticipate the risk-benefit 
ratio of anticoagulation. This results in both the underuse 
and overuse of anticoagulation in patients as well as 
uncertainty over whether to use anticoagulation in 
paroxysmal AF. This review looks at optimising 
anticoagulation by improving the assessment of bleeding 
risk and by improving the assessment of stroke risk.  The 
percutaneous occlusion of the left atrial appendage is an 
emerging alternative to oral anticoagulation therapy.  
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AF: Atrial Fibrillation, CHADS2: Congestive heart 
failure, hypertension, age ≥75 years,  diabetes mellitus, 
previous stroke/transient ischaemic attack score, 
CHA2DS2-VASc: Congestive heart failure, hypertension, 
age ≥75 years, diabetes mellitus, previous stroke or 
transient ischemic attack, vascular disease, age 65 to 74 
years, female sex score, CMBs: cerebral microbleeds, 
ECG: Electrocardiography, ICH: intracerebral 
haemorrhage, LAA: left atrial appendage, MRI: 
Magnetic Resonance Imaging,  NOACs: non-vitamin K 
antagonist oral anticoagulants,  NT-proBNP: N-terminal 
pro-brain natriuretic peptide OAC: oral anticoagulants, 
PAF: Paroxysmal Atrial Fibrillation  
 
Introduction 
Atrial fibrillation (AF) is the most frequent 
sustained cardiac arrhythmia in clinical practice.1 In 
2010 it was estimated that globally 33.5 million 
individuals had AF, and the prevalence is estimated to 
be increasing worldwide.2 AF patients have a five-fold 
increase in their risk of ischemic stroke and strokes in 
AF patients have a higher chance of being fatal or 
disabling.3 Oral anticoagulants are recommended for 
stroke prophylaxis but stroke risk varies in AF and risk 
reduction effect must be balanced against haemorrhage 
risk.  Not all patients with AF have a stroke risk high 
enough to warrant anticoagulation. It may be difficult for 
the clinician to decide whether to anticoagulate a 
specific patient and anticoagulation is not always 
appropriately managed.4 To use anticoagulants properly 
it is also important to look for occult intermittent AF in 
specific circumstances. When intermittent AF is 
detected, there is uncertainty about which patients 
should be anticoagulated.5 This review will explore these 
key areas in which anticoagulation therapy may be 
optimised in AF patients.  
 
Anticoagulants, stroke risk reduction and 
haemorrhage 
The main anticoagulants, warfarin and the non-
vitamin K antagonist oral anticoagulants (NOACs) - 
Dabigatran, Apixaban and Rivaroxaban, recommended 
for the use of stroke prophylaxis, have all been found to 
be effective in preventing stroke but are all associated 
with an increased risk of bleeding.6 Successful use of 
anticoagulant treatment therefore needs to be able to 
achieve a balance between decreasing the risk of stroke 
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and increasing the risk of bleeding.7    
The risks of stroke and bleeding in AF patients 
depend on individuals’ vascular risk factors and clinical 
risk stratification schemes have been developed to assess 
the risk of stroke and bleeding.8 These include the 
CHADS2  (Congestive heart failure, hypertension, age 
≥75 years,  diabetes mellitus, previous stroke/transient 
ischaemic attack) score (Table 1) and the newer 
CHA2DS2-VASc (congestive heart failure, hypertension, 
age ≥75 years, diabetes mellitus, previous stroke or 
transient ischemic attack, vascular disease, age 65 to 74 
years, female sex) score (Table 2) to assess the risk of 
stroke and the HAS-BLED tool (Table 3) to assess the 
risk of bleeding.4  
 
Table 1: Assessment of Stroke (CHADS2) in Atrial 
Fibrillation Patients 
 
Table 2: Assessment of Stroke (CHA2DS2-VASc) in 






















Table 3: Assessment of Bleeding Risk (HAS-BLED) 
in Atrial Fibrillation Patients 
HAS-BLED Tool Score 
Hypertension 1 
Abnormal liver function 1 
Abnormal renal function 1 
Previous Stroke 1 
History of predisposition to 
bleeding 
1 
Labile INR 1 
Elderly (> 65) 1 
Drugs (Antiplatelets or NSAIDs) 1 
Harmful Alcohol intake 1 
Under the CHADS2 tool AF patients are considered 
low risk for stroke if the score is 0 and high risk if the 
score is ≥ 2.9 Under the newer CHA2DS2-VASc tool, AF 
patients are considered to have a low risk of stroke if 
they are below 65 with no risk factors other than their 
sex (this equates to a CHA2DS2-VASc score of 0 for 
men or 1 for women) and high risk if they have a 
CHA2DS2-VASc of ≥ 2,9-10 (this means any woman 
over 65 or men with any added risk factor) 
Anticoagulation is indicated in any patient with a history 
of stroke. 
 
Underuse of anticoagulants  and optimisation  
The underuse of oral anticoagulants in patients with 
a high risk of stroke can result in the occurrence of 
preventable ischemic stroke.11 A recent study found that 
use of anticoagulants is poorly associated with the stroke 
risk. The international Global anticoagulant registry in 
the field (GARFIELD)  study examined the use of 
warfarin and NOACs and found 38% of patients 
classified as having a high risk of stroke (CHADS2 score 
≥2)  did not receive anticoagulant therapy. Similarly 
when risk was assessed using the CHA2DS2-VASc 
score, 40.7% of the patients with a high risk of stroke 
did not receive anticoagulant therapy.12  
Underuse of anticoagulants is often due to an over-
estimation of bleeding risks. The ESC and NICE 
guidelines recommend that the bleeding risk of patients 
with AF should be assessed using the HAS-BLED score.  
13 The HAS-BLED score offers better prediction of 
bleeding compared with other bleeding risk scores such 
as HEMORR2HAGES (Table 4) and ATRIA  (Table 5) 
but the effectiveness of HAS-BLED has largely been 
based on the prediction of bleeding events that were not 
considered major, i.e. gastrointestinal bleeds as opposed 
CHADS2 Risk Score 
Congestive Heart Failure 1 
Hypertension 1 
Age > 75 1 
Diabetes 1 
Stroke or TIA 2 
CHA2DS2-VASc Risk Score 
CHF or LVEF < 40% 1 
Hypertension 1 





Vascular Disease 1 
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to intracerebral haemorrhage (ICH).14 A recent study 
showed that patients are prepared to accept 4.4 systemic 
major bleeds for every stroke prevented, so that the 
stroke risk reduction cannot be balanced against non-
intracerebral bleeds.15 The estimation of bleeding risk is 
difficult as many of the known factors that increase 
bleeding risk, overlap with stroke risk factors. Given that 
the prediction of bleeding risk can be challenging and 
that the HAS-BLED score does not directly address the 
bleeding event of greatest concern (ICH), an alternative 
approach to predicting the risk of bleeding such as brain 
MRI maybe necessary.14   MRI can show cerebral 
microbleeds (CMBs) that are small areas of brain 
haemorrhage that may increase the risk of future 
intracerebral haemorrhage in AF patients.16-17. A recent 
meta-analysis of CMBs found the risk of ICH to increase 
up to 8 fold in ischemic stroke patients with CMBs 
compared to those without.18 
There is limited data on cohorts exposed to OAC 
therapy but the presence of CMBs have been found to 
increase the risk of warfarin associated ICH. A case 
control study comparing warfarin users with ICH and 
warfarin users without ICH, found the number of CMBs 
were much higher in the ICH group (79.2% vs. 22.9%). 
19 Assessing the microbleeds location and underlying 
cause of the ICH can help decide whether to restart 
anticoagulation after an ICH.19 In patients on warfarin 
there is an increased risk of ICH with lobar microbleeds 
compared with deep CMBs.20 Cerebral amyloid 
angiopathy and a high risk of recurrence are associated 
with lobar ICH in the aged population, whereas deep 
ICH are often associated with hypertension. Controlling 
the blood pressure can permit the resumption of 
anticoagulation in the case of deep ICH, whereas the 
presence of multiple lobar microbleeds on MRI will 
prevent the resumption.19 
Findings such as these have prompted the 
recommendation that MRI screening for anticoagulation 
therapy should be necessary in patients with AF ≥ 60.20 
Larger prospective cohort studies such as the ongoing 
CROMIS-2 study are expected to establish whether 
brain MRI has the capacity to predict an individual’s 
ICH risk and improve the personalised management of 
AF patients.18 The use of MRI in such a way may have 
significant appeal, despite the economical and logistical 
issues, particularly for clinicians whose concern for 
haemorrhagic risk takes precedence over the benefit of 
stroke prevention when prescribing anticoagulants.14  In 
patients in whom the risk of bleeding is too high, the 
percutaneous occlusion of the left atrial appendage 
(LAA) is an emerging alternative to oral anticoagulation 
therapy for stroke prevention as the LAA has been 
recognised as a major site of clot formation in non-
valvular AF patients.21 Haemorrhagic change in an 
ischaemic infarct should not be a reason not to 
anticoagulate. 
Table 4: Assessment of Bleeding Risk 
(HEMORR(2)HAGES) in Atrial Fibrillation Patients 
 
HEMORR(2)HAGES Score 
Hepatic or renal disease 1 
Ethanol abuse 1 
malignancy 1 
Older age 1 
Reduced platelet count or 
function 
1 
Rebleeding risk 2 
Hypertension 1 
Anaemia 1 
Genetic factors 1 
Excessive Fall risk  1 
Stroke  1 
Table 5: Assessment of Bleeding Risk (ATRIA) in Atrial 
Fibrillation Patients 
 
ATRIA Score  
Anaemia 3 
Severe renal disease 3 
age ≥ 75 years 2 
Previous haemorrhage 1 
hypertension 1 
 
Overuse of anticoagulants  and optimisation  
The overuse of anticoagulant therapy in low risk 
patients puts this population at an unnecessary risk of 
complications associated with bleeding.9 The Global 
Anticoagulant Registry in the FIELD (GARFIELD) 
study which focused on the use of warfarin and NOACs, 
found when risk was assessed with the CHADS2 score, 
42.5% of low risk patients were on anticoagulant therapy 
and when risk was assessed with the CHA2DS2-VASc 
score even though fewer patients appeared to be on 
anticoagulant therapy (38.7%) the risk of overuse 
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Barnes et al.9 found in their study that only 3.4% of 
low risk patients (CHADS2 score of 0) were receiving 
inappropriate therapy with warfarin for stroke 
prophylaxis in AF, when procedure-based indications 
were considered. However the value of 3.4% in this 
study was achieved by utilising the total number of non-
valvular AF patients involved in the study as the 
denominator. Whereas the earlier studies referred to in 
the paper such as Meiltz et al.’s study,22 used the total 
number of patients with a CHADS2 score of 0 as the 
denominator .The use of a larger denominator by Barnes 
et al.9 may render the results misleading and thus the 
overuse of anticoagulants in low risk AF patients can 
still be seen as a problem.   
  The underuse and overuse of anticoagulants suggest 
that, the CHADS2 and CHA2DS2-VASc tools are often 
not followed appropriately. Furthermore the tools have a 
limited capacity for the prediction of stroke as shown by 
their low c statistic scores (0.549 to 0.638).7 A c- 
statistic of 1.0 offers perfect discrimination whereas a 
value of 0.5 means a tool is no better than random 
chance at making a prediction.23 In light of this, 
biomarkers have been suggested as prognostic tools.     
Elevated troponin and NT-proBNP levels are each 
independently associated with the rates of stroke and the 
addition of the biomarkers to the CHADS2and 
CHA2DS2VASc clinical risk tools improves the 
prognostic ability of the tools 24. The level of natriuretic 
peptides in AF can be associated with atrial dysfunction, 
which is an established risk factor for thrombus 
formation in AF. Currently no established explanation 
exists for the association between stroke and elevated 
troponin levels but the availability of troponin 
measurements in most hospitals means it a promising 
prognostic tool.7  
The addition of both cardiac biomarkers to the 
CHADS2 and CHA2DS2VASc scores, improves the c 
statistic more compared to the individual addition of the 
biomarkers.25-26 In the future there may be a role for a 
multi marker strategy to improve risk stratification. It is 
important to note however that the results from these 
trials were derived from clinical trial populations and 
therefore it may not be possible to immediately 
extrapolate the findings to the general AF population 
until further trials are performed.27 BNP levels show 
considerable variability and despite being a significant 
risk factor in a study population it is less likely that an 
isolated result in any patient will be a significantly 
robust stroke risk marker. 
 
Use of Anticoagulation in Paroxysmal AF and 
Optimisation 
The utilisation of anticoagulation in paroxysmal AF 
also poses problems. The terminology surrounding the 
different patterns of AF have been inconsistent in the 
past, however recent guidelines have proposed a 
consensus definition for the different types of AF.28 
Paroxysmal AF has been defined as episodes of AF that 
spontaneously end within 7 days. Persistent AF has been 
defined as episodes lasting more than 7 days and 
permanent AF has been defined as AF without any 
intervening periods of sinus rhythm.29 The minimum 
duration of an AF episode that is acceptable as a risk 
factor for stroke is still unsettled,5 however guidelines 
state anticoagulation should be considered after 48 hours 
of AF29 Current guidelines recommend that the pattern 
of AF should not determine whether a patient is given 
anticoagulation or not. Patients with each type of AF 
should receive oral anticoagulant therapy dependant on 
the presence of individual stroke risk factors. 10 Previous 
data comparing the stroke risk of paroxysmal and 
permanent AF is believed to be restricted due to 
methodological problems, such as the use of small 
sample sizes or differing rates of anticoagulation in 
patients with differing patterns of AF.  
Recent larger trials have found the stroke risk to be 
higher in non-paroxysmal AF compared to paroxysmal 
AF. A recent study found that within each CHA2DS2-
VASc category the outcome rates of embolic events 
were lower in paroxysmal AF compared to persistent 
and permanent AF.28 It is proposed that the electrical 
abnormalities and pathophysiological changes that 
predispose patients to thrombus formation and stroke are 
more pronounced in patients with permanent rather than 
paroxysmal AF. Thus the pattern of AF can be seen as a 
marker of increased susceptibility of stroke.30 
In the above study patients with a CHA2DS2-VASc 
score of ≥ 2 and paroxysmal AF still had a minimum 
stroke risk of 2%, confirming recommendations that 
patients with a high clinical risk score of stroke should 
be anticoagulated regardless of the pattern of AF.28 To 
optimise anticoagulation therapy in AF patients it is 
recommended that in patients where it is not clear 
whether a patient would benefit from anticoagulant 
therapy, the pattern of AF should be taken into account. 
  In low risk patients with paroxysmal AF the benefit 
of anticoagulation may not outweigh the risk of 
bleeding.28 Similar recommendations have been made by 
Steinberg et al.31 who prompt for further research 
regarding more thorough stroke prevention in patients 
with persistent AF compared to paroxysmal AF.  
The detection of PAF itself is challenging due to its 
short, unpredictable and often asymptomatic nature.32 
There are a variety of strategies and devices available to 
detect PAF which include intermittent, event-triggered 
and continuous monitoring through both external and 
implanted devices. Although it has been established that 
prolonged ECG monitoring detects more paroxysmal AF 
the optimum method and duration for detection remain 
unclear.33 This is an area which would aid from further 
research and help to further the optimisation of 
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Optimal utilisation of anticoagulation in AF 
patients is challenging. The overuse and underuse of 
anticoagulation suggests uncertainty exists regarding 
when anticoagulation is appropriate. The current clinical 
risk stratification tools are still suboptimal at predicting 
the risks of stroke and of bleeding and this reduces the 
ability to accurately balance the risks of anticoagulation 
in an individual. The presence of novel promising risk 
stratification tools (biomarkers and MRI) and new 
techniques for risk assessment may help to manage 
anticoagulation better in the future. In our current state 
of knowledge, it is important to apply the CHADS2 or 
CHA2DS2VASC as well as the HAS-BLED scores as 
faithfully as possible to gauge the potential risk of stroke 
and bleeding. Gauging the risk of intracerebral 
haemorrhage is more of an art but patients with prior 
cerebral haemorrhage and multiple microbleeds should 
not be anticoagulated. In these patients and in patients 
with contraindications to anticoagulants, LAA occlusion 
should be considered. 
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